Editor’s note: The approvals are listed from most to least recent.
- Biogen’s Aduhelm — The first treatment approved by the FDA to slow cognitive decline from Alzheimer’s disease and the first new Alzheimer’s drug approved in nearly two decades.
- Novo Nordisk’s Wegovy — An injectable drug designed for chronic weight management in adults with obesity.
- ProMetic Biotherapeutics’ Ryplazim — A drug designed to treat patients with plasminogen deficiency type 1, also called hypoplasminogenemia, a disorder that can impair normal tissue and organ function and that may lead to blindness.
- Amgen’s Lumakras — The first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.
- Johnson & Johnson’s Rybrevant — The first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations.
- AstraZeneca’s Farxiga — Oral tablets intended to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.